🔎 Trials Near Me

Gara Jalqabaatti › Kansarii Ovarii › Florida › Orlando

Qorannoo klinikaalii Kansarii Ovarii Orlando, FL keessatti

Qorannoo 22 Kansarii Ovarii f Orlando fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.

Takkalaa qorannoo (Ingiliffa)

Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Namoota walitti qabaa jiraSadarkaa 1/2
  • Advent Health, Orlando
Umuriin 12 fi ol · Saalaa hunda · Haaromfame 02-Onk-2026 · NCT04585750

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

Namoota walitti qabaa jiraSadarkaa 2
  • AdventHealth Medical Group Oncology Research at Celebration, Kissimmee · Miili 16 fagaatti
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 01-Onk-2026 · NCT06172478

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

Namoota walitti qabaa jiraSadarkaa 1
  • AdventHealth Cancer Institute, Orlando
Umuriin 19 fi ol · Saalaa hunda · Haaromfame 01-Onk-2026 · NCT06586957

Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer

Namoota walitti qabaa jiraQorannoo ilaalaa
  • Orlando Health, Orlando
Umuriin 18 fi ol · Dubartoota · Haaromfame 29-Ful-2026 · NCT05051722

A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Namoota walitti qabaa jiraSadarkaa 2
  • Site 0308 - Advent Health, Orlando
  • Site 0241 - Florida Cancer Specialist - North, Altamonte Springs · Miili 9 fagaatti
Umuriin 18 fi ol · Dubartoota · Haaromfame 29-Ful-2026 · NCT05128825

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

Namoota walitti qabaa jiraSadarkaa 3
  • AdventHealth Orlando, Orlando
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 22-Ful-2026 · NCT07213804

A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer

Namoota walitti qabaa jiraSadarkaa 2
  • Orlando Health Cancer Institute Gynecologic Cancer Center - Orlando /ID# 278623, Orlando
Umuriin 18 fi ol · Dubartoota · Haaromfame 22-Ful-2026 · NCT07059845

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

Namoota walitti qabaa jiraSadarkaa 1
  • Sara Cannon Research Institute Lake Nona, Orlando
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 21-Ful-2026 · NCT05983432

A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

Namoota walitti qabaa jiraSadarkaa 3
  • Orlando Health Winnie Palmer Hospital for Women and Babies ( Site 0085), Orlando
Umuriin 18 fi ol · Dubartoota · Haaromfame 17-Ful-2026 · NCT07318558

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

Namoota walitti qabaa jiraSadarkaa 1/2
  • Florida Cancer Specialists - Lake Nona, Orlando
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 17-Ful-2026 · NCT07109726

Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

Namoota walitti qabaa jiraSadarkaa 2
  • Advent Health Cancer Institute, Orlando
Umuriin 18 fi ol · Dubartoota · Haaromfame 14-Ful-2026 · NCT06787612

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

Namoota walitti qabaa jiraSadarkaa 1
  • Sarah Cannon Research Institute - Lake Nona Florida, Orlando
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 10-Ful-2026 · NCT06293898

Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.

Namoota walitti qabaa jiraSadarkaa 1
  • Sarah Cannon Research Institute at Florida Cancer Specialists, Orlando
Umuriin 18 fi ol · Dubartoota · Haaromfame 03-Ful-2026 · NCT07755436

A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9

Namoota walitti qabaa jiraSadarkaa 1/2
  • Florida Cancer Specialists, Orlando
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 27-Hag-2026 · NCT07186842

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

Namoota walitti qabaa jiraSadarkaa 3
  • AdventHealth Cancer Institute, Orlando
Umuriin 18 fi ol · Dubartoota · Haaromfame 26-Hag-2026 · NCT05281471

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

Namoota walitti qabaa jiraSadarkaa 3
  • Orlando Health Cancer Institute, Orlando
  • Health Central, Ocoee · Miili 10 fagaatti
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 07-Hag-2026 · NCT06580314

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

Namoota walitti qabaa jiraSadarkaa 1
  • Florida Cancer Specialists, Orlando
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 06-Ado-2026 · NCT04389632

Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)

Namoota walitti qabaa jiraSadarkaa 3
  • AdventHealth Cancer Institute, Orlando
Umuriin 18 fi ol · Dubartoota · Haaromfame 02-Ado-2026 · NCT06819007

Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

Namoota walitti qabaa jiraSadarkaa 1/2
  • Florida Cancer Specialists, Orlando
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 01-Elb-2026 · NCT05735080

A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

Namoota walitti qabaa jiraSadarkaa 1
  • Dren Investigational Site, Orlando
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 07-Ama-2026 · NCT06999187

A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors

Namoota walitti qabaa jiraSadarkaa 1
  • Exelixis Clinical Site #8, Orlando
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 05-Ful-2025 · NCT05932862

Qorannoo Kansarii Ovarii magaalota biroo keessatti

Qorannoo biroo Orlando keessatti

Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.